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Abstract
The objective of this study was to examine HLA-DRB1  and
HLA-DQB1  genotypes in patients with severe extra-articular
rheumatoid arthritis (ExRA) and to compare them with the
genotypes of rheumatoid arthritis (RA) patients without extra-
articular manifestations. Patients with severe ExRA were
recruited from a large research database of patients with RA,
from two cohorts of prevalent RA cases, and from a regional
multicenter early RA cohort. Cases with ExRA manifestations (n
= 159) were classified according to predefined criteria.
Controls (n = 178) with RA but no ExRA were selected from the
same sources. Cases and controls were matched for duration of
RA and for clinical center. PCR based HLA-DRB1 and HLA-
DQB1 genotyping was performed using the Biotest SSP kit,
with additional sequencing in order to distinguish DRB1*04
subtypes. Associations between alleles and disease
phenotypes were tested using multiple simulations of random
distributions of alleles. There was no difference in global
distribution of HLA-DRB1  and  HLA-DQB1  alleles between
patients with ExRA and controls. DRB1*0401 (P = 0.003) and
0401/0401 homozygosity (P = 0.002) were more frequent in
Felty's syndrome than in controls. The presence of two HLA-
DRB1*04  alleles encoding the shared epitope (SE) was
associated with ExRA (overall odds ratio 1.79, 95% confidence
interval 1.04–3.08) and with rheumatoid vasculitis (odds ratio
2.44, 95% confidence interval 1.22–4.89). In this large sample
of patients with ExRA, Felty's syndrome was the only
manifestation that was clearly associated with HLA-
DRB1*0401. Other ExRA manifestations were not associated
with individual alleles but with DRB1*04  SE double dose
genotypes. This confirms that SE genes contribute to RA
disease severity and ExRA. Other genetic and environmental
factors may have a more specific impact on individual ExRA
manifestations.
Introduction
Rheumatoid arthritis (RA) is a systemic inflammatory disease
that, in a substantial proportion of patients, is associated with
the development of extra-articular manifestations. These extra-
articular RA (ExRA) manifestations can have a defining impact
on disease outcome, including increased premature mortality
compared with RA in general [1-4]. Severe ExRA occurs both
in patients recently diagnosed with RA and in those with long-
standing disease [2]. Suggested predictors of ExRA include
clinical, serologic, and genetic factors [5].
There is strong evidence of a role for genetic factors in the eti-
ology of RA [6-8], and genetic polymorphisms are probably
involved in the wide variation in disease expression. As for
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most diseases classified according to a list of criteria, rather
than specific diagnostic tests, the disease phenotype in RA is
heterogeneous. The presence of disease susceptibility alleles
may define subsets of patients with different disease courses,
including patients with mild, nonerosive disease and those
with a true RA phenotype and progressive disease, with exten-
sive joint damage and ExRA manifestations. On the other
hand, genetic markers not related to disease susceptibility
may influence disease progression and risk for developing
ExRA.
HLA (human leukocyte antigen) alleles have been implicated
in a number of chronic inflammatory diseases. RA has been
associated with the 'shared epitope' (SE) of HLA-DRB1,
which includes DRB1*04 and DRB1*01 alleles [9]. Recent
genome-wide scanning studies using microsatellite loci have
confirmed that there is strong linkage between this region and
RA [10,11]. RA-associated HLA-DRB1*04 alleles have been
reported mainly in patients with severe disease [12-16]. A
meta-analysis of studies of disease progression in RA [17]
revealed an association between HLA-DRB1*04 and erosive
disease, and in a recently reported survey of an extensively
investigated cohort of patients with early RA [18] homozygos-
ity for HLA-DRB1*04 was a major predictor of development of
erosions. DRB1*04 alleles have also been specifically associ-
ated with ExRA [19-21], and a specific impact of DRB1*04
homozygosity has been suggested. Some authors have
reported an association with the 0401/0401  genotype
[21,22] whereas others have found the 0401/0404 genotype
to be more frequent among patients with ExRA [23]. These
discrepancies may reflect variability in the relative frequencies
of HLA-DRB1*0401 in different populations. For example, in
East Asian populations, in which DRB1*0401  is rare and
DRB1*0405 is the most frequent RA associated HLA-DRB1
genotype [24], the latter allele has also been reported to be
associated with an increased risk for ExRA manifestations
[25].
All previous studies of major histocompatibility class (MHC)
class II genes and ExRA have been based on small patient
samples, limiting the generalizability of the results. Most stud-
ies were not sufficiently powered to examine the effect of link-
age disequilibrium within the MHC, including HLA-DQB1
alleles. Previous investigations did not use consistent and well
characterized definitions of ExRA, which is a matter of vital
importance to the study of disease phenotypes in RA [26].
The purpose of this study was to investigate associations
between  HLA-DRB1  and  HLA-DQB1  alleles and severe
ExRA manifestations in a multicenter case-control study of
patients with well characterized disease. To our knowledge,
this is the largest sample of patients with severe ExRA ever
reported. We report that patients with ExRA manifestations
are more likely to carry a double dose of DRB1*04 SE alleles,
and we demonstrate that the impact of individual DRB1 alleles
is limited.
Materials and methods
Patients
Patients with severe ExRA according to predefined criteria
[2,3] were recruited from the rheumatology laboratory data-
base of the Mayo Clinic (Rochester, MN, USA), from two
clinic-based cohorts of patients with ExRA from Malmö Univer-
sity Hospital and Lund University Hospital (Sweden), and from
a Swedish multicenter early RA cohort (the Better AntiRheu-
matic PharmacOTherapy [BARFOT] cohort). ExRA manifesta-
tions studied included pericarditis, pleuritis, Felty's syndrome,
scleritis, episcleritis, glomerulonephritis, vasculitis-related neu-
ropathy, major cutaneous vasculitis, and vasculitis involving
other organs. Felty's syndrome was defined as RA-associated
neutropenia and splenomegaly, with other potential causes
excluded or unlikely. In addition, the criteria for severe ExRA
were modified to include RA-associated interstitial lung dis-
ease, as previously described [5]. Controls, defined as
patients with RA without current or previous signs of extra-
articular disease manifestations, in accordance with the same
criteria [2,3,5], were selected from the corresponding centers.
One patient with RA (control) was matched to each patient
with ExRA (case) according to duration of RA and clinical
center. All cases and controls fulfilled 1987 American College
of Rheumatology criteria for classification of RA [27].
Eighty-eight patients fulfilling the predefined criteria for ExRA
(see above) were identified from the Mayo Clinic rheumatology
laboratory database, and their medical case records were sub-
jected to a structured review, as previously described [22]. A
random sample of 184 patients with RA but without ExRA
were identified from this database after careful medical record
review. Controls from this sample were matched with cases
for duration of RA ± 5 years. DNA samples were available from
86 ExRA cases and 85 controls for HLA typing.
Another cohort of patients was recruited from a prospective
study of extra-articular disease manifestations and vascular
comorbidities in RA from the rheumatology outpatient clinic of
Malmö University Hospital. Consecutive patients with recently
diagnosed severe extra-articular disease manifestations were
invited to participate. Patients with non-extra-articular RA,
matched to extra-articular patients for age, sex and disease
duration (± 1 year), were selected from a community-based
register of RA patients in the city of Malmö [28] or from a com-
munity-based early RA inception cohort from the same area.
Samples from 28 patients with ExRA (cases) and 28 matched
patients with RA but without ExRA (controls) were available for
analysis. Thirty-five patients with ExRA (cases) and 42 patients
with RA but without extra-articular disease (controls), matched
for disease duration, from a case-control study of predictors of
ExRA at the University Hospitals in Malmö and Lund [22] were
also included in the analysis. Results of HLA-DR and HLA-DQAvailable online http://arthritis-research.com/content/7/6/R1386
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genotyping for some of these patients were reported previ-
ously [22].
In addition, patients were recruited from the BARFOT registry
[29], which includes patients participating in a structured pro-
gram for follow up of newly diagnosed RA in southern Swe-
den. This registry includes virtually all adult patients with new
onset of inflammatory polyarthritis within the catchment area of
the six participating rheumatology centers of the BARFOT pro-
gram (total population is approximately 1.5 million), including
patients fulfilling the 1987 American College of Rheumatology
classification criteria for RA [27]. From 1992 to 2001, a total
of 1,589 consecutive patients were recruited to the registry.
Referring rheumatologists are encouraged to report ExRA
manifestations occurring in these patients to the register. All
reported ExRA cases (n = 35) were reviewed and classified
according to the study criteria [2,3]. Of these, 26 patients ful-
filled the criteria for ExRA. Controls without ExRA were
matched to the cases by sex, age at inclusion, disease dura-
tion and, when possible, geographic region. All potential con-
trols were reviewed in order to ensure that they did not have a
history of ExRA. Samples for genotyping were available from
ten ExRA cases and 24 non-ExRA controls in this subset.
Data on serologic tests for rheumatoid factor (RF) and antinu-
clear antibodies (ANAs), and information on smoking status
are prospectively collected as part of a structured follow up of
patients in the BARFOT study. Data on these parameters for
patients from the other centers (Malmö, Lund and the Mayo
Clinic) were obtained by thorough review of all available clini-
cal records.
All patients gave informed consent to participate in the study.
The study was approved by the Research Ethics Committee at
Lund University and by the Institutional Review Board at the
Mayo Clinic.
Genotyping
DNA for HLA-DRB1/DQB1 typing of patients recruited from
the Mayo Clinic was isolated from peripheral blood mononu-
clear cells using the DNA Isolation Kit for Mammalian Blood
(Roche Applied Sciences, Indianapolis, IN, USA). For patients
from the Swedish RA cohorts, DNA was extracted from whole
blood using the QIAamp minikit (Qiagen, Hilden, Germany) at
the DNA/RNA Genotyping Laboratory, SWEGENE Resource
Center for Profiling Polygenic Diseases (Lund University and
Malmö University Hospital, Sweden). The purified DNA was
used for HLA-DRB1 and HLA-DQB1 determination with the
PCR-based Micro-SSP DRB and DQB generic typing trays
(Biotest AG, Dreiech, Germany). Because the DRB kit does
not detect HLA-DRB1*04 allelic variations, all samples that
were positive for HLA-DRB1*04 were re-amplified by PCR
using a primer set that amplified all HLA-DRB1*04 alleles: 5'-
GTTTCTTGGAGCAGGTTAAACA-3' (HLA-DRB1*04) and
5'-GCCGCTGCACTGTGAAGCTCTC-3' (HLA-DRB1
generic). Samples were then purified using the High Pure
PCR Product Purification Kit (Roche Applied Sciences) and
sequenced in the Mayo Clinic molecular biology core facility
on a PRISM 37 DNA Sequencer (Applied Biosystems, Foster
City, CA, USA) with the HLA-DRB1 primer as the initiating
primer. The specific HLA-DRB1*04 allele was then assigned
on the basis of the sequencing results. For the statistical anal-
ysis, the SE encoding rare DRB1*0401-like alleles *0409,
*0413, *0416 and *0421 were classified as *0401; alleles
*0408,  *0410  and  *0419  were classified as *0404. The
DRB1*0405 alleles were analyzed as a separate entity. All
other DRB1*04 alleles were classified as DRB1*04 non-SE
alleles.
Statistical analysis
The age at RA diagnosis and the duration of RA at inclusion in
ExRA cases and non-ExRA controls with RA were compared
using the t test. The sex distribution, the number of smokers
and the number of patients with a positive RF test or ANA test
at any time were compared between the cases and controls
using Pearson's χ2 statistic.
To compare the distribution of alleles between cases and con-
trols, we used Armitage's trend in proportions, which does not
treat the two alleles within a person as independent (i.e. it
does not assume Hardy-Weinberg equilibrium). This approach
reduces to the usual Pearson χ2 statistic for comparing allele
frequencies when genotype proportions match Hardy-Wein-
berg proportions [30], and is the preferred way to compare
allele frequencies [31]. However, the usual Armitage test for
trend is for only two alleles. A multivariate extension for more
than two alleles, which compares allele counts between cases
and controls, is based on the score statistic for logistic regres-
sion. For this score statistic, each subject receives a vector of
scores, where each element of the vector counts alleles of
each type. From this score statistic, we computed a global test
of association between case/control status and all alleles of
Table 1
Demographic data and clinical predictors of ExRA
ExRA Non-ExRA P
Number 159 178
Age at RA diagnosis 
(years; mean ± SD)
50.1 ± 14.4 50.4 ± 14.8 0.87
Disease duration (years; 
mean ± SD)
11.3 ± 11.2 12.5 ± 11.3 0.34
Male/female (n) 75/84 66/112 0.06
RF positivea (%) 87.2 58.3 <0.0001
ANA positiveb (%) 60.8 33.8 <0.0001
aInformation available for 149 extra-articular rheumatoid arthritis 
(ExRA) and 163 non-ExRA patients.
bInformation available from 120 ExRA and 151 non-ExRA patients. 
ANA, antinuclear antibody; RA, rheumatoid arthritis; RF, rheumatoid 
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HLA-DRB1 and HLA-DQB1 separately. Because the distribu-
tion of this statistic is not known, we performed simulations to
compute P values. The case/control status was randomly per-
muted, and the simulated statistic computed and compared
with the observed statistic. This simulation process was
repeated 1,000 times to compute P values, both for the maxi-
mum statistic and allele-specific Armitage trend tests. The dis-
tribution of combinations of HLA-DRB1 and DQ alleles (i.e.
the distribution of HLA-DRB1-DQ haplotypes) was similarly
compared in cases and controls.
To evaluate the association of single or double dose of HLA-
DRB1*04 SE subtypes with case/control status, or with a par-
ticular manifestation of ExRA, we used logistic regression to
calculate odds ratios (ORs) and 95% confidence interval (CI).
Results
A total of 159 patients with severe ExRA according to prede-
fined criteria [5,23] were identified. Forty-three patients had
vasculitis, defined as biopsy proven vasculitis or major cutane-
ous vasculitis diagnosed by a dermatologist. Additional sub-
groups analyzed were neuropathy (mononeuropathy or
polyneuropathy; n = 40), interstitial lung disease (n = 25),
Felty's syndrome (n = 21) and pericarditis (n = 27). These
were compared with 178 controls with non-extra-articular RA.
Disease duration and age at RA onset was similar in cases and
controls (mean 11.3 years versus 12.5 years for duration, and
mean 50.1 years versus 50.4 years for age at RA onset; Table
1). There was a trend toward a relative predominance of male
patients in the ExRA group (P = 0.06). However, this compar-
ison is skewed because of the matching of cases and controls
for sex in two of the subsamples. A positive test for RF (P <
0.0001) or ANAs (P < 0.0001) at any time were both signifi-
cantly associated with ExRA.
Some of the individual severe ExRA manifestations occurred
together more frequently than expected. Among the 21
patients with Felty's syndrome, three (14%) had evidence of
vasculitis. In the subset with vasculitis, 15 out of 43 (35%) had
neuropathy and seven (16%) had interstitial lung disease.
Overall effects of HLA-DRB1 alleles
The distribution of HLA-DRB1 was not significantly different
between ExRA cases and non-ExRA controls (global P = 0.19;
Table 2). The most frequent HLA-DRB1 allele in both groups
was HLA-DRB1*0401, and this allele tended to be more com-
mon among patients with ExRA (allele frequency 0.326 versus
0.263; P = 0.09). HLA-DRB1*0401 was significantly associ-
ated with Felty's syndrome (allele frequency 0.475; P = 0.003)
but not with other individual manifestations when compared
with non-extra-articular RA (Fig. 1). The rare allele HLA-
DRB1*12 was more common in the ExRA subgroup (allele fre-
quency 0.023 versus 0.003; P  = 0.02). The DRB1*0405
(allele frequency 0.019 versus 0.003; P  = 0.01) and
DRB1*0404 (allele frequency 0.119 versus 0.085; P = 0.14)
alleles were also more frequent in patients with ExRA than in
non-ExRA controls. One of the HLA-DRB1*04 alleles encod-
ing the SE (DRB1*0401, *0404, or *0405) was present in
105 out of 151 ExRA patients as compared with 96 out of 178
Table 2
Frequencies of HLA-DRB1 alleles in patients with ExRA 
compared with patients with non-extra-articular RA
HLA-DRB1 allele Allele frequency P
ExRA Non-ExRA
DRB1*01 0.119 0.130 0.74
DRB1*03 0.071 0.113 0.12
DRB1*0401 0.326 0.263 0.09
DRB1*0404 0.119 0.085 0.14
DRB1*0405 0.019 0.003 0.01
Non-SE DRB1*04 0.019 0.045 0.09
DRB1*07 0.052 0.065 0.54
DRB1*08 0.013 0.014 1.00
DRB1*09 0.023 0.011 0.23
DRB1*10 0.016 0.020 0.73
DRB1*11 0.036 0.054 0.28
DRB1*12 0.023 0.003 0.02
DRB1*13 0.042 0.045 0.83
DRB1*15 0.097 0.110 0.65
Global: P = 0.19. ExRA, extra-articular rheumatoid arthritis; SE, 
shared epitope.
Figure 1
Variation in frequency of HLA-DRB1*0401 by disease phenotype in RA Variation in frequency of HLA-DRB1*0401 by disease phenotype in 
RA. HLA-DRB1*0401 was significantly more frequent in patients with 
Felty's syndrome (P = 0.003) than in non-extra-articular rheumatoid 
arthritis (RA) controls, but patients with other manifestations did not dif-
fer significantly from controls. ExRA, extra-articular RA; ILD, interstitial 
lung disease; Neuro, vasculitis related neuropathy.Available online http://arthritis-research.com/content/7/6/R1386
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non-ExRA patients (OR 1.77, 95% CI 1.13–2.77). The impact
of the presence of DRB1*04 SE alleles on risk for ExRA was
variable for the different manifestations (Fig. 2). Patients with
RA and vasculitis were more likely to carry DRB1*04 SE alle-
les than patients with RA and no vasculitis (OR 2.07, 95% CI
1.00–4.25). Similar trends were found for Felty's syndrome
and neuropathy, but the associations were not significant (Fig.
2).
Effects of homozygosity for the shared epitope
The homozygous genotype HLA-DRB1*0401/0401 was sig-
nificantly more frequent in patients with Felty's syndrome
(genotype frequency 0.286; P = 0.002) and patients with peri-
carditis (genotype frequency 0.185; P = 0.043) than in non-
ExRA controls (frequency 0.068). Other ExRA manifestations
were not associated with any specific homozygous genotype.
The presence of two HLA-DRB1*04 SE alleles was signifi-
cantly associated with ExRA overall (OR 1.79, 95% CI 1.04–
3.08), Felty's syndrome (OR 2.63, 95% CI 1.04–6.63), and
vasculitis (OR 2.44, 95% CI 1.22–4.89) compared with
patients with RA who lacked these manifestations. By con-
trast, pericarditis, neuropathy, and interstitial lung disease
were not associated with double dose of HLA-DRB1*04 SE
alleles (Table 3).
Effects of HLA-DQB alleles
The distribution of HLA-DQB alleles was not significantly dif-
ferent between ExRA cases and non-ExRA controls (P = 0.11;
Table 4). The relatively rare allele HLA-DQ4 tended to occur
more frequently in ExRA cases (allele frequency 0.046 versus
0.014; P = 0.037). Other than that, there was no significant
difference in the occurrence of DQB alleles between patients
with ExRA overall or individual ExRA manifestations and non-
ExRA controls. There was no significant global difference in
the frequency of homozygous HLA-DQB genotypes between
cases and controls except for patients with ExRA and pericar-
ditis (P  = 0.04). HLA-DQ8/DQ8  homozygosity was more
common in patients with pericarditis than in non-ExRA patients
with RA (genotype frequency 0.120 versus 0.029; P = 0.021).
Analyses of linkage disequilibrium
Haplotype analysis indicated that the association between
ExRA and HLA-DRB1*04 SE homozygosity was due to the
importance of the DRB1*04  genotype, rather than being
secondary to associations with HLA-DRB1-DQB haplotypes
(data not shown). Similarly, the associations between Felty's
syndrome and DRB1*0401, and between pericarditis and
DQ8/DQ8  were not explained by DRB1-DQB  haplotype
associations.
Discussion
In this large sample of patients with severe ExRA, we found
Felty's syndrome to be associated with HLA-DRB1*0401.
There was no significant difference in the global distribution of
HLA-DRB1 or HLA-DQB  alleles compared with non-extra-
articular RA controls for any other manifestation or for ExRA
overall. Patients with severe ExRA were more likely to carry
HLA-DRB1*04 SE alleles, and genotypes featuring a double
dose of DRB1*04 SE alleles were associated with rheumatoid
vasculitis, Felty's syndrome, and all ExRA combined.
A number of studies have indicated a role for HLA-DR4
related genes in ExRA [26]. In Caucasians of Northern Euro-
pean origin, severe ExRA has been associated with
DRB1*0401/0401  homozygosity in particular [21,22]. In a
recent meta-analysis of HLA-DRB1  genotyping studies of
patients with RA-associated vasculitis conducted by Gorman
and coworkers [32], vasculitis was found to be associated
with the genotypes 0401/0401, 0401/0404, and 0401/0101.
In other meta-analyses by the same group, double dose of
DRB1*04 SE alleles was associated with radiographic signs
of progressive joint damage in northern European Caucasians
[17], but there was no significant association between SE and
the presence of rheumatoid nodules [33]. Taken together,
these findings indicate that DRB1*04 SE double gene dose is
associated with disease severity in RA, and that such geno-
types may contribute specifically to risk for severe ExRA
manifestations.
On the other hand, there was considerable heterogeneity
across individual ExRA manifestations. The association
between Felty's syndrome and DRB1*0401  is well
established [34,35]. In contrast, we did not observe any signif-
icant association with single or double DRB1*04 gene dose
for patients with pericarditis, neuropathy, or interstitial lung dis-
ease. This indicates that the importance of HLA-DRB1 alleles
may be variable for different manifestations, although our fail-
ure to detect an effect could be due to sample size or
selection.
Severe ExRA manifestations tend to cluster in individual
patients with RA [36]. The high prevalence of vasculitis in
patients with Felty's syndrome observed in the present study
is consistent with the literature [37], and may in part be due to
shared genetic factors such as HLA-DRB1*04 alleles. In a
Figure 2
ExRA manifestations among those carrying carrying HLA-DRB1*04  shared epitope alleles ExRA manifestations among those carrying carrying HLA-DRB1*04 
shared epitope alleles. Shown are odds ratios (ORs) with 95% confi-
dence intervals (CIs) for different extra-articular rheumatoid arthritis 
(ExRA) manifestations for patients carrying HLA-DRB1*04 shared 
epitope alleles. ILD, interstitial lung disease.Arthritis Research & Therapy    Vol 7 No 6    Turesson et al.
R1391
survey of the community-based Olmsted county RA cohort
[36] we found clustering of a number of different ExRA fea-
tures, including a frequent co-occurrence of vasculitis with
neuropathy and rheumatoid lung disease. We made similar
observations in the present study. Such clustering may be
explained by both genetic and environmental factors.
The association between HLA-DRB1 genotypes and RA dis-
ease severity, including ExRA, has been interpreted as reflect-
ing the importance of T cells in the pathogenesis of RA [26].
HLA-DR and other MHC molecules are involved in presenta-
tion of antigens to T cells, and in positive and negative selec-
tion of T cells in the thymus. Because there appears to be a
stoichiometric relationship between MHC molecules on the
cell surface and positive selection mechanisms in thymic mat-
uration of T cells, it has been suggested that the explanation
for the gene dose effect seen in ExRA is its effect on T-cell
diversity [21,38]. The T-cell repertoire in patients with RA is
markedly contracted, with less diversity and emergence of
dominant T-cell clonotypes [39]. T-cell abnormalities in
patients with ExRA include expansion of CD8+ large granular
lymphocytes [40] and of immunosenescent CD4+CD28- cells
[41,42], and extensive CD4+ infiltrates in RA-associated inter-
stitial pneumonitis [43]. The importance of HLA-DRB1 genes
and other genes with a role in T-cell selection and T-cell func-
tion for these phenomena require further study.
In accordance with previous studies, we found patients with
ExRA to be more likely to be RF positive and ANA positive
[22,44]. This suggests a role for both B cells and T cells, pos-
sibly including dysregulated B cell-T cell interaction, in ExRA.
New genetic associations that were not postulated and have
not been reproduced should be interpreted with caution.
Given the nonsignificant results of the global distribution tests,
the associations between ExRA and some rare DRB1 and
DQB1 alleles (i.e. DRB1*12 and DQ4) are probably due to
chance. The negative global test for HLA-DRB1  alleles in
ExRA overall also suggests that the impact of DRB1*04 SE on
the risk for severe ExRA manifestations is not strong, although
it is reproducible in separate patient samples.
The lack of association between ExRA and HLA-DQB1 alle-
les, and the lack of association with HLA-DRB1-DQB1 haplo-
types favors a specific role for HLA-DRB1 genes in ExRA,
rather than secondary associations due to linked genes. Nev-
ertheless, we cannot exclude the possibility that linkage dise-
quilibrium with other genes in MHC explain our results.
The patients included in this study were recruited from four dif-
ferent centers, and the background RA population from which
they were sampled is not fully characterized, at least not for the
patients seen at Lund University Hospital and at the Mayo
Clinic. On the other hand, these patients were recruited during
a period when there was particular interest in patients with
severe ExRA at each of the centers, suggesting that they
Table 3
The effect of homozygosity for HLA-DRB1*04 shared epitope alleles on risk for severe ExRA manifestations
Manifestations Homozygotes (yes/no; %) OR (95% CI) P
Cases with manifestation Controls without 
manifestation
All ExRA 39/116 (25) 28/149 (16) 1.79 (1.04–3.08) 0.04
Pericarditis 8/19 (29) 59/246 (19) 1.76 (0.73–4.19) 0.21
Felty's syndrome 8/13 (38) 59/252 (19) 2.63 (1.04–6.63) 0.04
Neuropathy 8/32 (20) 59/233 (20) 0.99 (0.43–2.25) 0.98
Interstitial lung disease 3/22 (12) 64/243 (21) 0.52 (0.15–1.78) 0.30
Vasculitis 15/28 (35) 52/237 (18) 2.44 (1.22–4.89) 0.01
CI, confidence interval; ExRA, extra-articular rheumatoid arthritis; OR, odds ratio.
Table 4
Frequencies of HLA-DQ alleles in patients with ExRA compared 
with patients with non-extra-articular RA
HLA-DQ allele Allele frequency P
ExRA Non-ExRA
DQ2 0.122 0.121 0.91
DQ3 0.017 0.029 0.50
DQ4 0.046 0.014 0.04
DQ5 0.129 0.188 0.06
DQ6 0.139 0.165 0.37
DQ7 0.252 0.249 1.00
DQ8 0.222 0.170 0.13
DQ9 0.066 0.043 0.22
Global: P = 0.11. ExRA, extra-articular RA.Available online http://arthritis-research.com/content/7/6/R1386
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should reflect the majority of patients with ExRA seen and be
representative of the ExRA population as a whole.
In multicenter studies of genetic markers, ethnic heterogeneity
of the studied patient samples must be considered. However,
the majority of the patients included at the Mayo Clinic were
Caucasians of northern European origin, similar to the patients
from southern Sweden. Thus, our result could be generalized
to RA patients with this ethnic background but not to other
populations.
Conclusion
In a study of a large sample of patients with ExRA, we have
confirmed an association between HLA-DRB1*0401  and
Felty's syndrome, but we found no association between ExRA
overall or other individual manifestations and specific HLA-
DRB1 alleles. Double dose HLA-DRB1*04 SE genotypes are
associated with a modestly increased risk for vasculitis and
other ExRA manifestations. Other genetic and environmental
factors are likely to be more important for the systemic features
of RA.
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